<DOC>
	<DOCNO>NCT02043652</DOCNO>
	<brief_summary>Background : The World Health Organization recommend antimalarial treatment policy evaluate every year check efficacy . P. vivax malaria common specie Brazil case concentrate Amazon Region Brazil . Objectives : Assess efficacy chloroquine primaquine treatment P. vivax infection Cruzeiro Sul , Acre , Brazil . Methods : An vivo drug efficacy study conduct Cruzeiro Sul , Acre State , Brazil . A total 117 study participant ≥5 year age parasitologically confirm P. vivax monoinfections treat supervision chloroquine ( CQ ) three day daily dose approximately 25 mg/Kg accordance Brazilian National Malaria Control guideline . For patient normal glucose 6 phosphate dehydrogenase activity level , investigator add primaquine dose 0.5mg/Kg per day 7 day . Clinical parasitologic parameter monitor 28-day follow-up period evaluate drug efficacy total period 168 day ( 6 month ) evaluate chance recrudescence , relapse , reinfection . Blood sample take measure CQ level blood Day 7 day failure , occur initial 28 day follow . In addition , blood sample collect filter paper first day day suspect failure help differentiate parasite genotype use technique base polymerase chain reaction . Results drug efficacy study use assist Brazilian Ministry Health assess national malaria treatment policy P. vivax malaria .</brief_summary>
	<brief_title>Plasmodium Vivax Efficacy Trial Cruzeiro Sul , Acre , Brazil</brief_title>
	<detailed_description>Background The impact malaria health economic development human population great tropic subtropics . The World Health Organization ( WHO ) estimate 216 million episode malaria 2010 , 174 million ( 81 % ) Africa . There total 655,000 malaria death worldwide , approximately 86 % child 5 year age ( WHO 2011 ) . Although majority death occur among child sub-Saharan Africa , malaria account considerable morbidity Americas , particularly Amazon Basin . Most country Americas adopt WHO Global Strategy Malaria Control , rely prompt effective antimalarial treatment major mean reduce malaria morbidity mortality ( WHO 2008 ) . The ultimate success strategy rest ability ministry health provide antimalarial drug proven efficacy . Although wide variety method use assess resistance antimalarial drug vivo method , vitro drug sensitivity testing , molecular analysis , national malaria control program rely data vivo efficacy trial assess efficacy current first- second-line drug decide charge malaria treatment policy need . The widely use approach conduct vivo drug efficacy trial Americas follow guideline WHO ( WHO 2009 ) modification recommend Pan American Health Organization study Americas ( PAHO 2003 ) . The goal study assess antimalarial drug currently use first-line treatment uncomplicated malaria . Much effort monitor antimalarial efficacy Americas do part Amazon Network Antimalarial Resistance Monitoring Amazon Malaria Initiative ( PAHO 2012 ) . This information critical guiding development rational antimalarial drug policy endemic area . Chloroquine-resistant P. vivax first report Papua New Guinea 1989 two Australian soldier ( Rieckmann , Davis et al . 1989 ) . In 1995 , study Irian Jaya , Indonesia show resistance least 44 % P. vivax patient treat chloroquine ( CQ ) ( Baird , Basri et al . 1995 ) . Several investigator report case CQ-resistant P. vivax South America . In 1996 , Guyana , Phillips et al . report three patient 25 mg/kg CQ fail eliminate parasitemia despite adequate therapeutic blood level CQ ( Phillips , Keystone et al . 1996 ) . Three year later , Brazilian Amazon region , Alecrim et al . report 12-year old girl P. vivax malaria continue parasitemia receiving supervise course 25mg/kg CQ ( Alecrim , Alecrim et al . 1999 ) . More recently , Soto et al . report three case CQ-resistant P. vivax Colombia ( Soto , Toledo et al . 2001 ) . In last two study , CQ blood level measure possible confirm adequate therapeutic level achieve . Because serious public health implication CQ-resistant P. vivax Americas , critically important limit report well-confirmed case . In case , require measurement CQ blood level genotyping parasite initial infection suspect recrudescence . P. falciparum vivo trial take advantage well-established molecular marker help differentiate case recrudescence reinfection , polymerase chain reaction ( PCR ) technique . Although universally accept technique purpose exist P. vivax , investigator plan use microsatellites , base pair repeat parasite genome , describe Imwong et al ( Imwong , Sudimack et al . 2006 ) . Investigators believe PCR-corrected analysis especially important context long follow-up period , six month , investigator aim study . Many malaria case Americas report Brazil ( Silveira 2001 ; Oliveira-Ferreira , Lacerda et al . 2010 ) . In 2011 , 293,701 malaria case report Brazilian National Reportable Disease Information System . Most case ( 99.7 % ) occur Amazon region , encompass state Acre , Amazonas , Amapa , Para , Maranhao , Mato Grosso , Roraima , Rondonia , Tocantins . In region , socio-economic environmental condition , presence natural breeding site abundance Anopheles mosquito , favor malaria transmission . Amazonas , Rondonia , Para , Acre state responsible 85.5 % malaria case 2011 accord Brazilian National Reportable Disease Information System . As region world , malaria seasonal Brazil , case increase rainy season ( Costa 2009 ) . In 2011 , 87,6 % malaria case Brazil due P. vivax alone , 11,3 % P. falciparum alone , approximately 1.1 % due mixed infection two specie . P. malariae rarely see Brazil . Acre state saw huge increase malaria case 2003 2004 2004 2005 , 153 % 63 % , respectively ( Cesario Cesario 2006 ) . The Acre municipality Cruzeiro Sul , Rodrigues Alves , Mancio Lima municipalities responsible 67.7 % malaria case state 2006 , malaria epidemic take place region . Table 1 show absolute number malaria case Brazil Acre state respective annual parasitologic index ( API ) , number positive malaria slide per 1,000 resident per year . Although currently evidence CQ-resistant P. vivax Cruzeiro Sul , Acre State , Brazil , Ministry Health would like assess efficacy CQ primaquine treatment uncomplicated P. vivax malaria part effort study antimalarial drug resistance within country . This practice accordance current WHO recommendation ( WHO 2009 ) . Objectives - To assess therapeutic efficacy CQ primaquine treatment P. vivax malaria Cruzeiro Sul , Acre State , Brazil . - Estimate recrudescence reinfection rate P. vivax infection parasite clearance CQ primaquine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>1 . Age ≥5 year ; Body weight &lt; 120 kg ; document fever ( axillary temperature &gt; 37.5o C ) history fever previous 48 hour absence another obvious cause fever , pneumonia , otitis medium , etc ; Monoinfection P. vivax parasitemia 250 100,000 asexual parasites/µl determine microscopic examination thick thin peripheral blood smear ; Informed consent patient parent/guardian ( &lt; 18 year ) , assent child ( age 7 17 year inclusive ) , patient 5 6 year old need assent ; Willingness part patient return clinic and/or receive home visit regular checkup 6month ( 168 day ) followup period ; Place residence within 3045 minute study site . 1 . Presence malaria danger sign ; presence underlie chronic severe disease ( e.g. , cardiac , renal , hepatic disease , HIV/AIDS , tuberculosis , malnutrition ) ; History hypersensitivity reaction drug test ; Current pregnancy ( either selfreported pregnant enrollment positive urine pregnancy test time enrollment ) , previous pregnancy exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>